Agile Therapeutics (AGRX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AGRX Stock Forecast

Agile Therapeutics stock forecast is as follows: an average price target of $1.00 (represents a -33.77% downside from AGRX’s last price of $1.51) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

AGRX Price Target

The average price target for Agile Therapeutics (AGRX) is $1.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential -33.77% downside from AGRX's last price of $1.51.

AGRX Analyst Ratings

Buy

According to 3 Wall Street analysts, Agile Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AGRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Agile Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 26, 2022	Caroline Palomeque	Maxim Group	$1.00	$0.54	85.19%	-33.77%

The latest Agile Therapeutics stock forecast, released on Jul 26, 2022 by Caroline Palomeque from Maxim Group, set a price target of $1.00, which represents a 85.19% increase from the stock price at the time of the forecast ($0.54), and a -33.77% decrease from AGRX last price ($1.51).

Agile Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.51	$1.51	$1.51
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Agile Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Agile Therapeutics's last price of $1.51. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 22, 2023	Maxim Group		Buy	Upgrade
Jun 29, 2023	H.C. Wainwright	Buy	Buy	Hold
Dec 30, 2022	Cantor Fitzgerald	Buy	Buy	Hold
Jul 12, 2022	H.C. Wainwright	Buy	Buy	Hold

Agile Therapeutics's last stock rating was published by Maxim Group on Sep 22, 2023. The company Upgrade its AGRX rating from "null" to "Buy".

Agile Therapeutics Financial Forecast

Agile Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Revenue	-	-	-	-	-	-	-	-	$3.62M	$6.66M	-	$3.81M	$4.00M	$3.00M	$2.13M	$1.76M	$1.51M	$1.29M	$1.19M	$116.00K	$749.00K
Avg Forecast	$17.72M	$17.06M	$15.75M	$15.10M	$11.26M	$9.38M	$7.50M	$4.13M	$4.07M	$6.77M	$4.63M	$3.40M	$3.13M	$2.33M	$1.98M	$1.22M	$1.51M	$1.46M	$1.13M	$802.80K	$1.01M
High Forecast	$17.72M	$17.06M	$15.75M	$15.10M	$11.26M	$9.38M	$7.50M	$4.13M	$4.07M	$6.77M	$4.63M	$3.40M	$3.13M	$2.33M	$1.98M	$1.22M	$1.51M	$1.46M	$1.13M	$802.80K	$1.01M
Low Forecast	$17.72M	$17.06M	$15.75M	$15.10M	$11.26M	$9.38M	$7.50M	$4.13M	$4.07M	$6.77M	$4.63M	$3.40M	$3.13M	$2.33M	$1.98M	$1.22M	$1.51M	$1.46M	$1.13M	$802.80K	$1.01M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	0.89%	0.98%	-	1.12%	1.28%	1.29%	1.07%	1.44%	1.00%	0.88%	1.05%	0.14%	0.74%

Agile Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $4.13M, with a low forecast of $4.13M, and a high forecast of $4.13M. AGRX's average Quarter revenue forecast represents a 14.16% increase compared to the company's last Quarter revenue of $3.62M (Dec 23).

Agile Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	$-4.05M	$-4.00M	-	$-6.67M	$-6.85M	$-7.28M	$-10.80M	$-14.98M	$-21.94M	$-15.22M	$-16.09M	$-15.66M	$-16.59M
Avg Forecast	$-10.60M	$-10.21M	$-9.42M	$-9.03M	$-6.73M	$-5.61M	$-4.49M	$-2.47M	$-2.43M	$-4.05M	$-2.77M	$-2.03M	$-1.87M	$-1.40M	$-1.19M	$-732.24K	$-904.13K	$-874.77K	$-678.16K	$-16.41M	$-602.18K
High Forecast	$-10.60M	$-10.21M	$-9.42M	$-9.03M	$-6.73M	$-5.61M	$-4.49M	$-2.47M	$-2.43M	$-4.05M	$-2.77M	$-2.03M	$-1.87M	$-1.40M	$-1.19M	$-732.24K	$-904.13K	$-874.77K	$-678.16K	$-13.12M	$-602.18K
Low Forecast	$-10.60M	$-10.21M	$-9.42M	$-9.03M	$-6.73M	$-5.61M	$-4.49M	$-2.47M	$-2.43M	$-4.05M	$-2.77M	$-2.03M	$-1.87M	$-1.40M	$-1.19M	$-732.24K	$-904.13K	$-874.77K	$-678.16K	$-19.69M	$-602.18K
Surprise %	-	-	-	-	-	-	-	-	1.66%	0.99%	-	3.29%	3.66%	5.21%	9.12%	20.46%	24.27%	17.40%	23.73%	0.95%	27.54%

undefined analysts predict AGRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Agile Therapeutics's previous annual EBITDA (undefined) of $NaN.

Agile Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	$-4.47M	$-799.00K	-	$-3.61M	$-13.28M	$-22.05M	$-13.04M	$-11.77M	$-24.36M	$-16.77M	$-17.64M	$-17.13M	$-17.62M
Avg Forecast	-	-	-	-	$685.62K	$-274.25K	$-1.23M	$-3.29M	$-6.31M	$-12.62M	$-33.90M	$-51.42M	$-75.42M	$-150.84M	$-1.27B	$-2.06B	$-2.06B	$-2.64B	$-2.96B	$-17.94M	$-3.07B
High Forecast	-	-	-	-	$685.62K	$-274.25K	$-1.23M	$-3.29M	$-6.31M	$-12.62M	$-33.90M	$-51.42M	$-75.42M	$-150.84M	$-1.27B	$-2.06B	$-2.06B	$-2.64B	$-2.96B	$-14.35M	$-3.07B
Low Forecast	-	-	-	-	$685.62K	$-274.25K	$-1.23M	$-3.29M	$-6.31M	$-12.62M	$-33.90M	$-51.42M	$-75.42M	$-150.84M	$-1.27B	$-2.06B	$-2.06B	$-2.64B	$-2.96B	$-21.53M	$-3.07B
Surprise %	-	-	-	-	-	-	-	-	0.71%	0.06%	-	0.07%	0.18%	0.15%	0.01%	0.01%	0.01%	0.01%	0.01%	0.95%	0.01%

Agile Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AGRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Agile Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	$5.42M	$7.48M	-	$7.75M	$8.87M	$8.38M	$10.44M	$14.55M	$16.49M	$12.76M	$15.83M	$13.06M	$1.58M
Avg Forecast	$243.09M	$234.09M	$216.08M	$207.08M	$154.41M	$128.68M	$102.94M	$56.62M	$55.82M	$92.85M	$63.46M	$46.60M	$42.87M	$32.01M	$27.18M	$16.79M	$20.73M	$20.06M	$15.55M	$11.01M	$13.81M
High Forecast	$243.09M	$234.09M	$216.08M	$207.08M	$154.41M	$128.68M	$102.94M	$56.62M	$55.82M	$92.85M	$63.46M	$46.60M	$42.87M	$32.01M	$27.18M	$16.79M	$20.73M	$20.06M	$15.55M	$11.01M	$13.81M
Low Forecast	$243.09M	$234.09M	$216.08M	$207.08M	$154.41M	$128.68M	$102.94M	$56.62M	$55.82M	$92.85M	$63.46M	$46.60M	$42.87M	$32.01M	$27.18M	$16.79M	$20.73M	$20.06M	$15.55M	$11.01M	$13.81M
Surprise %	-	-	-	-	-	-	-	-	0.10%	0.08%	-	0.17%	0.21%	0.26%	0.38%	0.87%	0.80%	0.64%	1.02%	1.19%	0.11%

Agile Therapeutics's average Quarter SG&A projection for Mar 24 is $56.62M, based on 1 Wall Street analysts, with a range of $56.62M to $56.62M. The forecast indicates a 944.56% rise compared to AGRX last annual SG&A of $5.42M (Dec 23).

Agile Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	$-0.00	$-0.00	-	$-3.96	$-16.10	$-29.80	$-144.56	$-188.90	$-0.26	$-0.18	$-0.20	$-0.20	$-0.20
Avg Forecast	-	-	-	-	$0.10	$-0.04	$-0.18	$-0.48	$-0.92	$-1.84	$-4.95	$-7.50	$-11.00	$-22.00	$-185.00	$-300.00	$-300.00	$-385.00	$-432.00	$-428.00	$-448.00
High Forecast	-	-	-	-	$0.10	$-0.04	$-0.18	$-0.48	$-0.92	$-1.84	$-4.95	$-7.50	$-11.00	$-22.00	$-185.00	$-300.00	$-300.00	$-385.00	$-432.00	$-428.00	$-448.00
Low Forecast	-	-	-	-	$0.10	$-0.04	$-0.18	$-0.48	$-0.92	$-1.84	$-4.95	$-7.50	$-11.00	$-22.00	$-185.00	$-300.00	$-300.00	$-385.00	$-432.00	$-428.00	$-448.00
Surprise %	-	-	-	-	-	-	-	-	0.00%	0.00%	-	0.53%	1.46%	1.35%	0.78%	0.63%	0.00%	0.00%	0.00%	0.00%	0.00%

According to undefined Wall Street analysts, Agile Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AGRX previous annual EPS of $NaN (undefined).

Agile Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EVOK	Evoke Pharma	$4.59	$18.00	292.16%	Buy
ASRT	Assertio	$0.93	$3.00	222.58%	Buy
AQST	Aquestive Therapeutics	$3.85	$10.00	159.74%	Buy
CYTH	Cyclo Therapeutics	$0.66	$0.95	43.94%	Buy
AMRX	Amneal Pharmaceuticals	$8.07	$11.50	42.50%	Buy
LFCR	Lifecore Biomedical	$7.47	$6.50	-12.99%	Buy

AGRX Forecast FAQ

Is Agile Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Agile Therapeutics (AGRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of AGRX's total ratings.

What is AGRX's price target?

Agile Therapeutics (AGRX) average price target is $1 with a range of $1 to $1, implying a -33.77% from its last price of $1.51. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Agile Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AGRX stock, the company can go down by -33.77% (from the last price of $1.51 to the average price target of $1), down by -33.77% based on the highest stock price target, and down by -33.77% based on the lowest stock price target.

Can Agile Therapeutics stock reach $2?

AGRX's average twelve months analyst stock price target of $1 does not support the claim that Agile Therapeutics can reach $2 in the near future.

What are Agile Therapeutics's analysts' financial forecasts?

Agile Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $32.27M (high $32.27M, low $32.27M), average EBITDA is $-19.303M (high $-19.303M, low $-19.303M), average net income is $-4.114M (high $-4.114M, low $-4.114M), average SG&A $442.65M (high $442.65M, low $442.65M), and average EPS is $-0.6 (high $-0.6, low $-0.6). AGRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $65.63M (high $65.63M, low $65.63M), average EBITDA is $-39.263M (high $-39.263M, low $-39.263M), average net income is $0 (high $0, low $0), average SG&A $900.35M (high $900.35M, low $900.35M), and average EPS is $0 (high $0, low $0).

Did the AGRX's actual financial results beat the analysts' financial forecasts?

Based on Agile Therapeutics's last annual report (Dec 2023), the company's revenue was $19.59M, beating the average analysts forecast of $18.86M by 3.88%. Apple's EBITDA was $-19.884M, beating the average prediction of $-11.283M by 76.23%. The company's net income was $-14.465M, missing the average estimation of $-104M by -86.12%. Apple's SG&A was $28.27M, missing the average forecast of $258.73M by -89.07%. Lastly, the company's EPS was $-0.0067, missing the average prediction of $-15.205 by -99.96%. In terms of the last quarterly report (Dec 2023), Agile Therapeutics's revenue was $3.62M, missing the average analysts' forecast of $4.07M by -11.16%. The company's EBITDA was $-4.05M, beating the average prediction of $-2.434M by 66.38%. Agile Therapeutics's net income was $-4.467M, missing the average estimation of $-6.308M by -29.18%. The company's SG&A was $5.42M, missing the average forecast of $55.82M by -90.29%. Lastly, the company's EPS was $-0.0015, missing the average prediction of $-0.92 by -99.84%